Moderna & Merck shares soar on cancer vaccine

Moderna and Merck’s mRNA cancer vaccine showed positive results in a late-stage melanoma trial. The vaccine could be available as soon as next year if regulators approve it. Moderna shares surged as much as 160% following the results. LiveNOW’s Mike Pache spoke about the medical breakthrough, and how the market responded to the news, with Barron’s Mackenzie Tatananni.